The forecasted sales data for Cardiac Glycosides in Austria indicates a stable performance from 2024 to 2026 with values maintaining at 200 thousand USD. However, there is a significant drop in sales from 2027 to 2028, with values halving to 100 thousand USD. Compared to 2023, the series suggest a substantial decline in the market, highlighting a negative trend in the later years. Year-on-year projections show no variation from 2024 to 2026, but a major decrease of 50% from 2026 to 2027 and stable low values thereafter. The CAGR over the forecast period reveals an overall declining trend in the market.
Future trends to watch for include potential market saturation, changes in healthcare policies, advancements in alternative treatments, and broader economic factors that could influence the demand for Cardiac Glycosides. Stakeholders should closely monitor these factors to adapt strategies accordingly.
